Psoriasis is a chronic immuno-inflammatory condition where an overactive immune system triggers severe inflammation and rapid skin cell turnover. Current treatment pathways are strictly stratified by disease severity: mild symptoms are managed with topical creams, whereas moderate-to-severe cases require systemic treatment, historically dominated by injectable biological agents.

The core innovation of Icotyde is its oral formulation. If successfully finalized, it offers the systemic strength of advanced biologicals in a simple daily pill. Primary advantages include eliminating routine injections, easing drug storage requirements, and substantially improving long-term patient adherence. However, medical experts emphasize that promising trial data does not mean an immediate, universally available remedy.